Allergy Liquid Antihistamine
cGMP Deviations: Potential product contamination with Burkholderia cepacia (B.cepacia) and Ralstonia pickettii (R. pickettii).
Yes — there is an active recall. 8 ongoing FDA recalls mention Diphenhydramine (49 total). Check the affected lots below.
Recalls are matched by product description. A recall usually affects specific lots, not every package of Diphenhydramine. “Active” means an FDA recall is still ongoing; “closed” means it was terminated or completed. Checked against openFDA on Oct 10, 2026.
cGMP Deviations: Potential product contamination with Burkholderia cepacia (B.cepacia) and Ralstonia pickettii (R. pickettii).
CGMP Deviations: Recall as a precautionary measure due to potential risk of product contamination with the bacteria B. cepacia.
CGMP Deviations: Recall as a precautionary measure due to potential risk of product contamination with the bacteria B. cepacia.
CGMP Deviations: Lack of stability data and controls to support the manufacturers assigned retest or expiration date in firm's container/closure system.
CGMP Deviations: Recall initiated as a precautionary measure due to a potential risk of product contamination with the bacteria B. cepacia.
CGMP Deviations: Recall initiated as a precautionary measure due to a potential risk of product contamination with the bacteria B. cepacia.
Subpotent: This product is being recalled due to low out of specification assay results at the 9 month time point.
Subpotent
Lack of Assurance of Sterility: Sterility of product is not assured.
Labeling: Label Mix-Up; Bottles of Mucinex Fast-Max liquid are correctly labeled on the front of the label, however the back of the bottle where the Drug Facts labeling is, is missing certain Active Ingredients such as acetaminophen, phenylephrine, dextromethorphan, diphenhydramine, and/or guaifenesin. As a result certain safety warnings associated with those ingredients may also be missing.
Microbial Contamination of a Non-Sterile Product: Kit component is contaminated with Burkholderia multivorans.
Lack of sterility assurance.
Incorrect/Undeclared Excipients: Specific drug products were compounded with an incorrect solvent.
Presence of Precipitate; small amounts of diphenhydramine precipitated out of solution
Presence of Precipitate; small amounts of diphenhydramine precipitated out of solution
Presence of Precipitate: Small amounts of diphenydramine and mannitol precipitated out of solution.
Subpotent Drug: This lot is being recalled because of out-of-specification test results for Diphenhydramine citrate.
Labeling: Label Mixup; diphenhydrAMINE HCl, Tablet, 25 mg may be potentially mislabeled as ATORVASTATIN CALCIUM, Tablet, 40 mg, NDC 00378212177, Pedigree: AD33897_10, EXP: 5/9/2014; ATORVASTATIN CALCIUM, Tablet, 10 mg, NDC 00378201577, Pedigree: W002774, EXP: 6/6/2014; PRENATAL MULTIVITAMIN/ MULTIMINERAL, Tablet, NDC 51991056601, Pedigree: W003511, EXP: 6/21/2014; VENLAFAXINE, Tablet, 25 mg
Presence of Foreign Substance: The products are being recalled because they may contain foreign substances.
Presence of Foreign Substance: The products are being recalled because they may contain foreign substances.
Presence of Foreign Substance: The products are being recalled because they may contain foreign substances.
Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Labeling: Not Elsewhere Classified; foil label on immediate blister pack indicates active ingredient as Chlorpheniramine rather than Diphenhydramine
Lack of Assurance of Sterility: Franck's Lab Inc. initiated a recall of all Sterile Human Drugs distributed between 11/21/2011 and 05/21/2012 because FDA environmental sampling revealed the presence of microorganisms and fungal growth in the clean room where sterile products were prepared.
Free recall alerts
Tell us what you take. When FDA posts a recall announcement or classifies a recall for one of your medications, we email you in plain English, with what to check. No account needed.